Genmab A/S (GNMSF) Profit After Tax (2018 - 2026)

Genmab A (GNMSF) has 6 years of Profit After Tax data on file, last reported at $53.0 million in Q1 2026.

• Quarterly Profit After Tax fell 72.82% year-over-year to $53.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 25.53% YoY) and the FY2025 annual result came in at $963.0 million, down 15.0% from the prior year.
• Profit After Tax eased to $53.0 million in Q1 2026, from $932.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $932.0 million in Q3 2025 to a low of $53.0 million in Q1 2026.
• A 3-year average of $411.3 million and a median of $395.0 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax soared 60.41% — and 2026, when it tumbled 72.82%.
• Tracing GNMSF's Profit After Tax over 3 years: stood at $581.0 million in 2024, then soared by 60.41% to $932.0 million in 2025, then slumped by 94.31% to $53.0 million in 2026.
• The last three Profit After Tax figures came in at $53.0 million (Q1 2026), $932.0 million (Q3 2025), and $531.0 million (Q2 2025), per Business Quant data.